Abstract
Background: There is suggestive evidence that inflammation is (IRRS) was developed, and its association with survival was related to ovarian cancer survival. However, more research is assessed using Cox proportional hazards models in the remaining needed to identify inflammation-related factors that are associated 50% of the data. with ovarian cancer survival and to determine their combined Results: There was a statistically significant trend of increasing effects. risk of death per quartile of the IRRS [HR ¼ 1.09; 95% confidence Methods: This analysis used pooled data on 8,147 women with interval (CI), 1.03–1.14]. Women in the upper quartile of the IRRS invasive epithelial ovarian cancer from the Ovarian Cancer had a 31% higher death rate compared with the lowest quartile (95% Association Consortium. The prediagnosis inflammation-related CI, 1.11–1.54). exposures of interest included alcohol use; aspirin use; other Conclusions: A higher prediagnosis IRRS was associated with an nonsteroidal anti-inflammatory drug use; body mass index; increased mortality risk after an ovarian cancer diagnosis. Further environmental tobacco smoke exposure; history of pelvic inflaminvestigation is warranted to evaluate whether postdiagnosis expomatory disease, polycystic ovarian syndrome, and endometriosis; sures are also associated with survival. menopausal hormone therapy use; physical inactivity; smoking Impact: Given that pre- and postdiagnosis exposures are often status; and talc use. Using Cox proportional hazards models, the correlated and many are modifiable, our study results can ultimately relationship between each exposure and survival was assessed in motivate the development of behavioral recommendations to 50% of the data. A weighted inflammation-related risk score enhance survival among patients with ovarian cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 443-452 |
Number of pages | 10 |
Journal | Cancer Epidemiology Biomarkers and Prevention |
Volume | 31 |
Issue number | 2 |
DOIs | |
State | Published - Feb 2022 |
ASJC Scopus subject areas
- Epidemiology
- Oncology
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival. / for the Ovarian Cancer Association Consortium.
In: Cancer Epidemiology Biomarkers and Prevention, Vol. 31, No. 2, 02.2022, p. 443-452.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival
AU - for the Ovarian Cancer Association Consortium
AU - Brieger, Katharine K.
AU - Phung, Minh Tung
AU - Mukherjee, Bhramar
AU - Bakulski, Kelly M.
AU - Anton-Culver, Hoda
AU - Bandera, Elisa V.
AU - Bowtell, David D.L.
AU - Cramer, Daniel W.
AU - DeFazio, Anna
AU - Doherty, Jennifer A.
AU - Fereday, Sian
AU - Fortner, Renee Turzanski
AU - Gentry-Maharaj, Aleksandra
AU - Goode, Ellen L.
AU - Goodman, Marc T.
AU - Harris, Holly R.
AU - Matsuo, Keitaro
AU - Menon, Usha
AU - Modugno, Francesmary
AU - Moysich, Kirsten B.
AU - Qin, Bo
AU - Ramus, Susan J.
AU - Risch, Harvey A.
AU - Rossing, Mary Anne
AU - Schildkraut, Joellen M.
AU - Trabert, Britton
AU - Vierkant, Robert A.
AU - Winham, Stacey J.
AU - Wentzensen, Nicolas
AU - Wu, Anna H.
AU - Ziogas, Argyrios
AU - Khoja, Lilah
AU - Cho, Kathleen R.
AU - McLean, Karen
AU - Richardson, Jean
AU - Grout, Bronwyn
AU - Chase, Anne
AU - McKinnon Deurloo, Cindy
AU - Odunsi, Kunle
AU - Nelson, Brad H.
AU - Brenton, James D.
AU - Terry, Kathryn L.
AU - Pharoah, Paul D.P.
AU - Berchuck, Andrew
AU - Hanley, Gillian E.
AU - Webb, Penelope M.
AU - Pike, Malcolm C.
AU - Pearce, Celeste Leigh
N1 - Funding Information: E.V. Bandera reports grants from NIH NCI during the conduct of the study as well as personal fees from Pfizer outside the submitted work. A. DeFazio reports grants from National Health & Medical Research Council of Australia, Cancer Council of New South Wales, Cancer Council of Victoria, Cancer Council of Queensland, Cancer Council of South Australia, Cancer Council of Tasmania, and Cancer Foundation of Western Australia during the conduct of the study as well as grants from AstraZeneca outside the submitted work. S. Fereday reports grants from U.S. Army Medical Research and Materiel Command under DAMD17-01-1-0729, U.S. Army Medical Research and Materiel Command - W81XWH-16-2-0010, and AstraZeneca during the conduct of the study as well as grants from AstraZeneca outside the submitted work and paid consultancy for Geneseq Biosciences - not related to ovarian cancer. R. T. Fortner reports grants from German Federal Ministry of Education and Research during the conduct of the study. A. Gentry-Maharaj reports grants from The Eve Appeal (The Oak Foundation) and other support from MRC Core funding (MR_UU-12023) during the conduct of the study. E.L. Goode reports grants from NCI during the conduct of the study. U. Menon reports grants from Cancer Research UK (CRUK), The Eve Appeal, National Institute for Health Research (NIHR) Health Technology Assessment, University College London Global Challenges Research Fund Internal Small Grant, MRC Proximity to Discovery Industrial Connectivity Award, NIHR Biomedical Research Centre University College London Hospitals and other support from Abcodia Ltd outside the submitted work; in addition, U. Menon has a patent no. EP10178345.4 licensed. F. Modugno reports grants from NCI and Department of Defense during the conduct of the study. B. Qin reports grants from National Institute on Minority Health and Health Disparities, NIH outside the submitted work. J.M. Shildkraut reports grants from NIH/NCI during the conduct of the study. K.L. Terry reports grants from NIH and Department of Defense Congressionally Mandated Research Program during the conduct of the study. P.D.P. Pharoah reports grants from CRUK during the conduct of the study. P.M. Webb reports grants from U.S. Army Medical Research and Materiel Command, National Health & Medical Research Council of Australia during the conduct of the study as well as grants from AstraZeneca outside the submitted work. M.C. Pike reports grants from NCI during the conduct of the study. C.L. Pearce reports grants from NIH during the conduct of the study. No disclosures were reported by the other authors. Funding Information: The OCAC is supported by a grant from the Ovarian Cancer Research Fund thanks to donations by the family and friends of Kathryn Sladek Smith (PPD/RPCI.07 to A. Berchuck). The scientific development and funding for this project were in part supported by the U.S. NCI GAME-ON Post-GWAS Initiative (U19-CA148112 to C.L. Pearce and J.M. Schildkraut). Funding for individual studies: AUS: The Australian Ovarian Cancer Study (AOCS) was supported by the U.S. Army Medical Research and Materiel Command (DAMD17-01-1-0729 to D.D.L. Bowtell and P.M. Webb); National Health & Medical Research Council of Australia (199600, 400413 and 400281 to D.D.L. Bowtell and P.M. Webb); Cancer Councils of New South Wales, Victoria, Queensland, South Australia and Tasmania and Cancer Foundation of Western Australia (Multi-State Applications 191, 211 and 182 to D.D.L. Bowtell and P.M. Webb). AOCS gratefully acknowledges additional support from Ovarian Cancer Australia and the Peter MacCallum Foundation; D.D.L. Bowtell is supported by the National Health and Medical Research Council of Australia (NHMRC; APP1117044, APP1161198, APP1092856); P.M. Webb is supported by NHMRC Investigator Grant APP1173346; CON: NIH (R01-CA063678, R01-CA074850, and R01-CA080742 to H.A. Risch); DOV: NIH (R01-CA112523 and R01-CA87538 to J.A. Doherty); HAW: U.S. NIH (R01-CA58598, N01-CN-55424 and N01-PC-67001 to M.T. Goodman); HOP: University of Pittsburgh School of Medicine Dean’s Faculty Advancement Award (to F. Modugno), Department of Defense (DAMD17-02-1-0669 to F. Modugno), and NCI (K07-CA080668 to F. Modugno; P50-CA159981 and R01-CA126841 to K.B. Moysich; R01-CA95023 and MO1-RR000056 to F. Modugno and K.B. Moysich); MAY: NIH (R01-CA122443, P30-CA15083, and P50-CA136393 to E.L. Goode); Mayo Foundation; Minnesota Ovarian Cancer Alliance; Fred C. and Katherine B. Andersen Foundation (to E.L. Goode); NCO: National Institutes of Health (R01-CA76016 to A. Berchuck and J.M. Schildkraut) and the Department of Defense (DAMD17-02-1-0666 to A. Berchuck); NEC: NIH (R01-CA54419 and P50-CA105009 to D.W. Cramer) and Department of Defense (W81XWH-10-1-02802 to K.L. Terry); NJO: NCI (NIH-K07 CA095666, R01-CA83918, NIH-K22-CA138563, and P30-CA072720 to E.V. Bandera) and the Cancer Institute of New Jersey (to E.V. Bandera); UCI: NIH (R01-CA058860 to H. Anton-Culver) and the Lon V Smith Foundation (grant LVS-39420 to H. Anton-Culver); USC: NIH (P01CA17054, N01PC67010, N01CN025403 to A.H. Wu, M.C. Pike, and C.L. Pearce; P30CA14089 to A.H. Wu and M.C. Pike; R01CA61132 to M.C. Pike; R03CA113148 and R03CA115195 to C.L. Pearce); and California Cancer Research Program (00-01389V-20170 to M.C. Pike and C.L. Pearce; 2II0200 to A.H. Wu); M.C. Pike is partially supported by the NIH/NCI Support Grant P30 CA008748 to Memorial Sloan Kettering Cancer Center. We are grateful to the family and friends of Kathryn Sladek Smith for their generous support of the OCAC through their donations to the Ovarian Cancer Research Fund. We thank the study participants, doctors, nurses, clinical and scientific collaborators, health care providers, and health information sources who have contributed to the many studies contributing to this manuscript. Acknowledgements for individual studies: AUS: The AOCS also acknowledges the cooperation of the participating institutions in Australia, and the contribution of the study nurses, research assistants, and all clinical and scientific collaborators. The complete AOCS Study Group can be found at www.aocstudy. org. We would like to thank all of the women who participated in this research program; CON: The cooperation of the 32 Connecticut hospitals, including Stamford Hospital, in allowing patient access, is gratefully acknowledged. This study was approved by the State of Connecticut Department of Public Health Human Investigation Committee. Certain data used in this study were obtained from the Connecticut Tumor Registry in the Connecticut Department of Public Health. The authors assume full responsibility for analyses and interpretation of these data; NJO: Drs. Sara Olson, Lisa Paddock, and Lorna Rodriguez, and research staff at the Rutgers Cancer Institute of New Jersey, Memorial Sloan-Kettering Cancer Center, and the New Jersey State Cancer Registry. Publisher Copyright: © 2022 American Association for Cancer Research
PY - 2022/2
Y1 - 2022/2
N2 - Background: There is suggestive evidence that inflammation is (IRRS) was developed, and its association with survival was related to ovarian cancer survival. However, more research is assessed using Cox proportional hazards models in the remaining needed to identify inflammation-related factors that are associated 50% of the data. with ovarian cancer survival and to determine their combined Results: There was a statistically significant trend of increasing effects. risk of death per quartile of the IRRS [HR ¼ 1.09; 95% confidence Methods: This analysis used pooled data on 8,147 women with interval (CI), 1.03–1.14]. Women in the upper quartile of the IRRS invasive epithelial ovarian cancer from the Ovarian Cancer had a 31% higher death rate compared with the lowest quartile (95% Association Consortium. The prediagnosis inflammation-related CI, 1.11–1.54). exposures of interest included alcohol use; aspirin use; other Conclusions: A higher prediagnosis IRRS was associated with an nonsteroidal anti-inflammatory drug use; body mass index; increased mortality risk after an ovarian cancer diagnosis. Further environmental tobacco smoke exposure; history of pelvic inflaminvestigation is warranted to evaluate whether postdiagnosis expomatory disease, polycystic ovarian syndrome, and endometriosis; sures are also associated with survival. menopausal hormone therapy use; physical inactivity; smoking Impact: Given that pre- and postdiagnosis exposures are often status; and talc use. Using Cox proportional hazards models, the correlated and many are modifiable, our study results can ultimately relationship between each exposure and survival was assessed in motivate the development of behavioral recommendations to 50% of the data. A weighted inflammation-related risk score enhance survival among patients with ovarian cancer.
AB - Background: There is suggestive evidence that inflammation is (IRRS) was developed, and its association with survival was related to ovarian cancer survival. However, more research is assessed using Cox proportional hazards models in the remaining needed to identify inflammation-related factors that are associated 50% of the data. with ovarian cancer survival and to determine their combined Results: There was a statistically significant trend of increasing effects. risk of death per quartile of the IRRS [HR ¼ 1.09; 95% confidence Methods: This analysis used pooled data on 8,147 women with interval (CI), 1.03–1.14]. Women in the upper quartile of the IRRS invasive epithelial ovarian cancer from the Ovarian Cancer had a 31% higher death rate compared with the lowest quartile (95% Association Consortium. The prediagnosis inflammation-related CI, 1.11–1.54). exposures of interest included alcohol use; aspirin use; other Conclusions: A higher prediagnosis IRRS was associated with an nonsteroidal anti-inflammatory drug use; body mass index; increased mortality risk after an ovarian cancer diagnosis. Further environmental tobacco smoke exposure; history of pelvic inflaminvestigation is warranted to evaluate whether postdiagnosis expomatory disease, polycystic ovarian syndrome, and endometriosis; sures are also associated with survival. menopausal hormone therapy use; physical inactivity; smoking Impact: Given that pre- and postdiagnosis exposures are often status; and talc use. Using Cox proportional hazards models, the correlated and many are modifiable, our study results can ultimately relationship between each exposure and survival was assessed in motivate the development of behavioral recommendations to 50% of the data. A weighted inflammation-related risk score enhance survival among patients with ovarian cancer.
UR - http://www.scopus.com/inward/record.url?scp=85124211978&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124211978&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-21-0977
DO - 10.1158/1055-9965.EPI-21-0977
M3 - Article
C2 - 34789471
AN - SCOPUS:85124211978
SN - 1055-9965
VL - 31
SP - 443
EP - 452
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 2
ER -